Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...
MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...
Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...
Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback